TrialLeukemia2024

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.

Patrick Derigs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.